- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05162066
BCX9930 for behandling av C3G, IgAN og PMN (RENEW) (RENEW)
En åpen undersøkelse, sikkerhet, tolerabilitet og konseptstudie av oral BCX9930-terapi hos personer med C3G, IgAN eller PMN
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Poitiers, Frankrike
- Investigative Site
-
Toulouse, Frankrike
- Investigative Site
-
-
-
-
-
Bari, Italia
- Investigative Site
-
Bergamo, Italia
- Investigative Site
-
Brescia, Italia
- Investigative Site
-
Turin, Italia
- Investigative Site
-
-
-
-
-
Barcelona, Spania
- Investigative Site #1
-
Barcelona, Spania
- Investigative Site #2
-
Madrid, Spania
- Investigative Site #1
-
Madrid, Spania
- Investigative Site #2
-
-
-
-
-
Oxford, Storbritannia
- Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Body weight ≥ 40 kilograms (kg)
- Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review
- An estimated glomerular filtration rate (eGFR) ≥ 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or ≥ 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation)
- Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit
- Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series
Exclusion Criteria:
- Known congenital deficiency of C1s, C1r, C1q, C2, or C4
- History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
- Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
- History of malignancy within 5 years prior to the screening visit
- Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
- Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
- Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: C3G cohort
Approximately 14 eligible participants with C3G will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
|
Eksperimentell: IgAN cohort
Approximately 14 eligible participants with IgAN will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
|
Eksperimentell: PMN cohort
Approximately 14 eligible participants with PMN will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent Change From Baseline in 24-hour uPCR at Week 12
Tidsramme: Baseline, Week 12
|
Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. |
Baseline, Week 12
|
|
Percent Change From Baseline in 24-hour uPCR at Week 24
Tidsramme: Baseline, Week 24
|
Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. |
Baseline, Week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prosentvis endring fra baseline i 24-timers urinproteinutskillelse
Tidsramme: Grunnlinje, uke 12, 24,
|
Grunnlinje, uke 12, 24,
|
|
|
Change From Baseline in Estimated Glomerular Filtration Rate
Tidsramme: Baseline, Weeks 12, 24
|
eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants ≥ 18 years old and by the bedside Schwartz formula for participants ≤ 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2). |
Baseline, Weeks 12, 24
|
|
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Tidsramme: From first dose up to safety follow-up period (Week 28)
|
An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Discontinued Due to a TEAE
Tidsramme: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE)
Tidsramme: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:
|
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE
Tidsramme: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study. TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death Participants with Grades 3 or 4 AEs were reported |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality
Tidsramme: From first dose up to safety follow-up period (Week 28)
|
Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug. CTCAE Grades for laboratory abnormalities include: Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death Participants with Grades 3 or 4 laboratory abnormality were reported. |
From first dose up to safety follow-up period (Week 28)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Carla M Nester, MD, MSA, FASN, University of Iowa Stead Family Children's Hospital
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Glomerulonefritt
- Nefritt
- Glomerulonefritt, IGA
- Glomerulonefritt, Membranøs
- Glomerulonefritt, Membranoproliferativ
Andre studie-ID-numre
- BCX9930-211
- 2020-005855-19 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .